Risperidone (Risperdal)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
US
  • Treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years (label section 1.3)FDA label
  • Bipolar Mania Monotherapy RISPERDAL is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see Clinical Studies (14.2) ] . Adjunctive Therapy RISPERDAL adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults [see Clinical Studies (14.3) ] .
    FDA label
Product first approved 1993Outside this platform's coverage

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (66)
Bipolar Disorder
NCT01977300 · University of British Columbia
2003-01 – 2011-08 · Bipolar I Disorder
What this study did
NCT00221403 · Children's Hospital Medical Center, Cincinnati
2004-09 – 2011-05 · Bipolar Disorder
What this study did
NCT02456454 · Nationwide Children's Hospital
2006-01 – 2010-06 · Bipolar Disorder
What this study did
NCT00177164 · University of Pittsburgh
2003-11 – 2009-12 · Bipolar I Disorder
What this study did
NCT00277654 · Lindner Center of HOPE
2004-02 – 2009-03 · Bipolar Disorder, Anxiety Disorder
What this study did
NCT00057681 · Washington University School of Medicine
2003-02 – 2008-12 · Bipolar Disorder
What this study did
NCT00176202 · University of Illinois at Chicago
2003-04 – 2008-01 · Bipolar Disorder
What this study did
NCT00246246 · Janssen-Ortho Inc., Canada
2004-01 – 2006-04 · Bipolar Disorder
What this study did
NCT00076115 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003-12 – 2005-12 · Bipolar Disorder
What this study did
NCT00399698 · Ohio State University
1999-05 – 2005-06 · Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit/Hyperactivity Disorder (ADHD), Intermittent Explosive Disorder, Impulse-Control Disorders, Adjustment Disorder, Bipolar Disorder, Pervasive Developmental Disorder
What this study did
NCT00097032 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-10 – 2005-05 · Bipolar Disorder
What this study did
NCT00249236 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-03 – 2001-12 · Bipolar Disorder, Manic Episode
What this study did
NCT00250367 · Janssen Pharmaceutica N.V., Belgium
1997-10 – 1999-11 · Bipolar Disorder, Manic Disorder
What this study did
NCT00253149 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
est. completion 1999-04 · Bipolar Disorders, Manic Disorder
What this study did
Schizophrenia
NCT06878833 · Lyndra Inc.
2025-04-18 – 2026-12-31 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT05779241 · Lyndra Inc.
2023-04-13 – 2023-12-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT03510325 · Shanghai Mental Health Center
2019-02-12 – 2023-09-27 · Schizophrenia
What this study did
NCT03230864 · H. Lundbeck A/S
2017-07-20 – 2019-02-05 · Treatment-resistant Schizophrenia
What this study did
NCT02717195 · H. Lundbeck A/S
2016-04 – 2018-10-08 · Schizophrenia
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT02758067 · H. Lundbeck A/S
2016-06 – 2016-06 · Schizophrenia
What this study did
NCT02109562 · Indivior Inc.
2014-04 – 2014-11 · Schizophrenia
What this study did
NCT01370291 · Xijing Hospital
2011-06 – 2013-12 · Schizophrenia
What this study did
NCT00347425 · Solvay Pharmaceuticals
2006-12 – 2008-02 · Schizophrenia and Schizoaffective Disorder
What this study did
NCT00246285 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-04 – 2006-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT00240708 · Janssen Pharmaceutical K.K.
2004-06 – 2006-04 · Schizophrenia
What this study did
NCT00034749 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-04 – 2006-03 · Schizophrenia
What this study did
NCT00088075 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-08 – 2005-12 · Schizophrenia
What this study did
NCT00495118 · Janssen, LP
2001-10 – 2005-03 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00034892 · AstraZeneca
2002-03 – 2005-03 · Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
What this study did
NCT00558298 · Janssen, LP
2000-02 – 2005-02 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00283179 · Taiwan Otsuka Pharm. Co., Ltd
2004-03 – 2004-12 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00161018 · University of Maryland, Baltimore
2003-11 – 2004-11 · Schizophrenia
What this study did
NCT00236587 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-11 – 2004-02 · Schizophrenia
What this study did
NCT00236353 · Janssen, LP
2002-05 – 2003-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT00305422 · AstraZeneca
2001-11 – 2003-01 · Schizophrenia
What this study did
NCT00236457 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2000-11 – 2002-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT00034775 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-08 – 2002-10 · Schizophrenia, Psychotic Disorders
What this study did
NCT00249119 · Janssen, LP
est. completion 1991-12 · Schizophrenia, Psychotic Disorder
What this study did
NCT00249132 · Janssen, LP
est. completion 1991-07 · Schizophrenia, Psychotic Disorders
What this study did
Other / comorbidity
NCT03227562 · Marion Trousselard
2017-09-01 – 2021-12-01 · Anxiety State
What this study did
NCT01624675 · Janssen Pharmaceutical K.K.
2012-09 – 2014-10 · Autistic Disorder in Children and Adolescents
What this study did
NCT00799383 · Chadi A. Calarge
2008-11 – 2014-03 · Risperidone-induced Hyperprolactinemia
What this study did
NCT00167154 · University of Alabama at Birmingham
2004-06 – 2008-08 · Depression
What this study did
NCT00174590 · Rush University Medical Center
2001-09 – 2007-08 · Major Depression With Psychotic Features
What this study did
NCT00254930 · Janssen-Cilag Ltd.
2003-09 – 2006-06 · Learning Disorders, Child Behavior Disorders
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT00910780 · Washington University School of Medicine
2009-11 – 2009-11 · Diabetes
What this study did
NCT00584701 · University of California, San Francisco
2008-01 – 2009-05 · Autism
What this study did
NCT00215241 · Duke University
2004-04 – 2006-07 · Post-Traumatic Stress Disorder
What this study did
Phase 2 (24)
Schizophrenia
NCT07152184 · University Hospital, Strasbourg, France
2026-10-01 – 2032-02-01 · Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
What this study did
NCT04567524 · Lyndra Inc.
2020-08-13 – 2020-12-22 · Schizophrenia Schizoaffective
What this study did
NCT02462473 · Janssen Research & Development, LLC
2015-05 – 2016-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01411085 · Dartmouth-Hitchcock Medical Center
2011-12 – 2014-09 · Schizophrenia, Alcoholism, Dual Diagnosis
What this study did
NCT01677377 · Indivior Inc.
2012-08 – 2013-04 · Schizophrenia
What this study did
NCT01083381 · Farzan Institute
2010-02 – 2011-04 · Schizophrenia
What this study did
NCT00921804 · AstraZeneca
2009-06 – 2010-05 · Schizophrenia
What this study did
NCT00073164 · Abbott
started 2003-07 · Schizophrenia
What this study did
NCT00202007 · Otsuka Beijing Research Institute
2005-02 – 2005-07 · Schizophrenia
What this study did
NCT00049946 · GlaxoSmithKline
2002-10 – 2003-04 · Schizophrenia
What this study did
Other / comorbidity
NCT04201834 · University of Rochester
2020-08-13 – 2023-12-30 · Huntington Disease, Chorea
What this study did
NCT03887754 · Minia University
2016-01 – 2018-12 · Autism Spectrum Disorder
What this study did
NCT01171937 · University of California, Los Angeles
2008-09 – 2016-12 · Autism
What this study did
NCT00099983 · US Department of Veterans Affairs
2006-10 – 2011-01 · Stress Disorders, Post-Traumatic
What this study did
NCT00385801 · Massachusetts General Hospital
2005-09 – 2010-09 · Cocaine Dependence
What this study did
NCT00206765 · Beth Israel Medical Center
2003-01 – 2005-07 · Major Depressive Disorder With Panic Attacks, Panic Disorder
What this study did
NCT00073658 · University of Pittsburgh
2000-01 – 2005-06 · Dementia
What this study did
NCT00000267 · National Institute on Drug Abuse (NIDA)
est. completion 2001-12 · Cocaine-Related Disorders
What this study did
NCT00004393 · National Center for Research Resources (NCRR)
1997-07 – 2000-09 · Tourette Syndrome
What this study did
NCT00000309 · Butler Hospital
1994-08 – 2000-01 · Cocaine-Related Disorders
What this study did
NCT00000317 · New York State Psychiatric Institute
1996-08 – 1999-07 · Cocaine-Related Disorders, Substance-Related Disorders
What this study did
NCT00000347 · National Institute on Drug Abuse (NIDA)
1997-07 – 1998-09 · Cocaine-Related Disorders
What this study did
NCT00000342 · National Institute on Drug Abuse (NIDA)
1996-07 – 1997-09 · Cocaine-Related Disorders
What this study did
NCT00000310 · National Institute on Drug Abuse (NIDA)
1996-01 – 1996-03 · Cocaine-Related Disorders
What this study did
Phase 1/2 (7)
Schizophrenia
NCT04418466 · Delpor, Inc.
2021-04-01 – 2023-02-10 · Schizophrenia
What this study did
NCT02650102 · Shanxi Medical University
2013-01 – 2016-12 · Schizophrenia
What this study did
NCT02538081 · VA Office of Research and Development
2015-08 – 2016-08 · Schizophrenia
What this study did
Other / comorbidity
NCT02535156 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2003-01 – 2015-01 · Schizotypal Personality Disorder
What this study did
NCT00133822 · Emory University
2004-04 – 2006-09 · Post-Traumatic Stress Disorders
What this study did
NCT00166595 · Children's Hospital Medical Center, Cincinnati
2003-02 – 2005-03 · Child Development Disorders, Pervasive
What this study did
NCT01282632 · Sunnybrook Health Sciences Centre
2002-08 – 2004-03 · Subjects Had Unipolar, Non-psychotic Major Depression
What this study did
Phase 1 (36)
Bipolar Disorder
NCT02087579 · Janssen Research & Development, LLC
2014-02 – 2014-12 · Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
What this study did
NCT00986336 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-02 – 2002-11 · Bipolar Disorder
What this study did
Schizophrenia
NCT05179525 · Rovi Pharmaceuticals Laboratories
2021-03-09 – 2021-09-17 · Schizophrenia
What this study did
NCT03790085 · Tianjin Medical University General Hospital
2018-09-01 – 2020-12-31 · Schizophrenia, Major Depressive Disorder, Anxiety Disorders
What this study did
NCT02051387 · Central Institute of Mental Health, Mannheim
2013-01 – 2017-08 · Schizophrenia
What this study did
NCT02019329 · Hoffmann-La Roche
2014-01 – 2014-08 · Schizophrenia
What this study did
NCT02768649 · Indivior Inc.
2011-04 – 2012-02 · Schizophrenia
What this study did
NCT00466310 · Duke University
2007-02 – 2011-01 · Schizophrenia
What this study did
NCT03730857 · Calo Psychiatric Center
2008-01 – 2008-12 · Schizophrenia
What this study did
NCT00269035 · GlaxoSmithKline
2005-06-21 – 2007-05-26 · Schizophrenia
What this study did
NCT00364429 · GlaxoSmithKline
2005-07 – 2005-07 · Schizophrenia
What this study did
NCT00645502 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003-06 – 2003-07 · Schizophrenia, Schizoaffective Disorders
What this study did
Other / comorbidity
NCT04071639 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-03-12 – 2024-12-31 · Huntington Disease
What this study did
NCT06218979 · Helsinki University Central Hospital
2023-12-08 – 2024-03-14 · Psychosis, Food-drug Interaction
What this study did
NCT05491720 · The National Brain Mapping Laboratory (NBML)
2020-08-15 – 2022-08-03 · Autism Spectrum Disorder
What this study did
NCT03837860 · The University of Texas Health Science Center at San Antonio
2019-04-01 – 2022-01-21 · Opioid Abuse, Unspecified, Opioid Dependence
What this study did
NCT04587115 · The University of Texas Health Science Center at San Antonio
2017-06-16 – 2020-01-01 · Addiction
What this study did
NCT03220867 · Xian-Janssen Pharmaceutical Ltd.
2017-12-11 – 2018-04-27 · Healthy
What this study did
NCT00000339 · National Institute on Drug Abuse (NIDA)
started 1996-06 · Cocaine-Related Disorders
What this study did
NCT02634463 · Janssen Research & Development, LLC
2015-11-09 – 2016-11-09 · Immunoassay, Antipsychotic
What this study did
NCT01320410 · Rovi Pharmaceuticals Laboratories
— · Healthy
What this study did
NCT01708616 · Hoffmann-La Roche
2012-11 – 2013-02 · Healthy Volunteer
What this study did
NCT01607762 · Janssen Research & Development, LLC
2012-02 – 2012-10 · Healthy
What this study did
NCT01259973 · Hospital Clinic of Barcelona
2011-02 – 2011-12 · Pharmacogenetics, Healthy
What this study did
NCT02012049 · Janssen Korea, Ltd., Korea
2009-08 – 2009-08 · Healthy
What this study did
NCT00698022 · Corcept Therapeutics
2008-11 – 2009-02 · Healthy
What this study did
NCT01064271 · Dr. Reddy's Laboratories Limited
2006-10 – 2006-10 · Healthy
What this study did
NCT01064232 · Dr. Reddy's Laboratories Limited
2006-10 – 2006-10 · Healthy
What this study did
NCT01155934 · Dr. Reddy's Laboratories Limited
2004-08 – 2004-08 · Healthy
What this study did
NCT01155921 · Dr. Reddy's Laboratories Limited
2004-08 – 2004-08 · Healthy
What this study did
NCT00255879 · University of California, San Diego
1999-01 – 2004-08 · Dyskinesia, Drug-Induced
What this study did
NCT00830349 · Teva Pharmaceuticals USA
2001-06 – 2004-07 · Healthy
What this study did
NCT00147394 · Children's Hospital Medical Center, Cincinnati
2001-12 – 2004-06 · Child Development Disorders, Pervasive
What this study did
NCT00829894 · Teva Pharmaceuticals USA
2001-06 – 2001-07 · Healthy
What this study did
Phase 4 (108)
Bipolar Disorder
NCT07665073 · Pakistan Institute of Medical Sciences
2027-06 – 2028-06 · Bipolar 1 Disorder
What this study did
NCT02918097 · Federal University of Rio Grande do Sul
2010-05 – 2015-09 · Bipolar Disorder
What this study did
NCT01050582 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2009-10 – 2011-07 · Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
What this study did
NCT00205699 · Washington University School of Medicine
2006-04 – 2011-07 · Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
What this study did
NCT00571688 · Vanderbilt University
2007-11 – 2009-02 · Bipolar Disorder
What this study did
NCT00203528 · Tuscaloosa Research & Education Advancement Corporation
2004-01 – 2007-02 · Substance Abuse, Bipolar Depression
What this study did
NCT00294255 · The University of Texas Health Science Center at San Antonio
2003-03 – 2006-10 · Bipolar Disorder
What this study did
NCT00167479 · University of South Florida
2003-09 – 2006-09 · Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
What this study did
NCT00048802 · Northwell Health
2002-08 – 2006-08 · Bipolar Disorder
What this study did
NCT00216554 · Janssen Korea, Ltd., Korea
2004-09 – 2006-03 · Bipolar Disorder
What this study did
NCT00181935 · Massachusetts General Hospital
2001-03 – 2004-07 · Bipolar Disorder, Mania
What this study did
NCT00182013 · Massachusetts General Hospital
2001-06 – 2004-02 · Bipolar Spectrum Disorder
What this study did
NCT00177567 · University of Pittsburgh
2001-07 – 2004-01 · Bipolar Disorder
What this study did
NCT00034580 · Eli Lilly and Company
2001-08 – 2002-08 · Bipolar Disorder
What this study did
Schizophrenia
NCT06969755 · Northwell Health
2024-09-04 – 2030-07-30 · Schizophenia Disorder
What this study did
NCT04478838 · Centre for Addiction and Mental Health
2022-06-06 – 2028-09-30 · Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy, Antipsychotic Agents
What this study did
NCT04940039 · Janssen-Cilag International NV
2021-07-22 – 2024-04-16 · Schizophrenia
What this study did
NCT03323437 · Weill Medical College of Cornell University
2017-09-15 – 2023-05-31 · Schizophrenia Spectrum and Other Psychotic Disorders
What this study did
NCT04446234 · Shanghai Mental Health Center
2021-05 – 2022-12-31 · Schizophrenia
What this study did
NCT03090503 · Fundación Marques de Valdecilla
2014-06 – 2021-06 · Schizophrenia, Psychotic Disorders, Psychosis
What this study did
NCT03883204 · Fundación Marques de Valdecilla
2015-01-01 – 2020-12 · Schizophrenia, Psychotic Disorders, Psychosis
What this study did
NCT02532491 · Fundación Marques de Valdecilla
2014-05 – 2020-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT03978832 · Indivior Inc.
2019-06-28 – 2020-05-12 · Schizophrenia
What this study did
NCT03713658 · Janssen Research & Development, LLC
2018-10-18 – 2019-12-02 · Schizophrenia
What this study did
NCT03568500 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-05-21 – 2019-09-06 · Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
What this study did
NCT02307396 · Technical University of Munich
2015-02-01 – 2016-06-22 · Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
What this study did
NCT00320671 · Northwell Health
2005-12 – 2015-12 · Schizophrenia
What this study did
NCT02593734 · University of Ghana Medical School
2013-07 – 2015-07 · Schizophrenia, Mood Disorders,, Anxiety Disorder
What this study did
NCT00314327 · Northwell Health
2006-04 – 2013-11 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
What this study did
NCT02021201 · Birte Glenthoj
2008-07 – 2013-07 · Schizophrenia
What this study did
NCT01109147 · Qualissima
2010-12 – 2013-05 · Schizophrenia, Undifferentiated Type
What this study did
NCT00333177 · University of California, Los Angeles
2006-03 – 2013-01 · Schizophrenia
What this study did
NCT00937261 · University of California, Irvine
2009-07 – 2011-01 · Schizophrenia
What this study did
NCT01284959 · Chonbuk National University Hospital
2010-06 – 2010-12 · Schizophrenia
What this study did
NCT01140620 · University of Manchester
2010-06 – 2010-12 · Healthy Volunteers, Schizophrenia
What this study did
NCT00712270 · Kettering Health Network
2005-04 – 2010-11 · Schizophrenia
What this study did
NCT00272597 · University of British Columbia
2005-09 – 2010-10 · Psychosis, Schizophrenia
What this study did
NCT00245206 · Veterans Medical Research Foundation
2005-08 – 2010-10 · Schizophrenia, Alzheimer's Disease, Dementia
What this study did
NCT00378092 · Janssen Cilag N.V./S.A.
2006-04 – 2010-03 · Schizophrenia
What this study did
NCT00305474 · Central South University
2003-12 – 2010-01 · Schizophrenia
What this study did
NCT00761670 · Sanofi
2008-09 – 2010-01 · Schizophrenia
What this study did
NCT00998608 · Kaohsiung Kai-Suan Psychiatric Hospital
2007-08 – 2009-10 · Schizophrenia
What this study did
NCT00044655 · Icahn School of Medicine at Mount Sinai
2001-07 – 2009-03 · Schizophrenia
What this study did
NCT01855074 · Janssen-Cilag Ltd.
2007-11 – 2009-02 · Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
What this study did
NCT00526877 · Johnson & Johnson Taiwan Ltd
2007-07-13 – 2009-01-31 · Schizophrenia, Schizoaffective Disorders
What this study did
NCT00299702 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-02 – 2009-01 · Schizophrenia, Psychotic Disorders
What this study did
NCT00498004 · Inje University
2007-08 – 2008-09 · Schizophrenia
What this study did
Early phase / not applicable (45)
Bipolar Disorder
NCT01878513 · Northwell Health
2009-09-23 – 2018-07-31 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
What this study did
NCT01786239 · Delbert Robinson
2013-05 – 2015-09 · Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
What this study did
NCT00746252 · University of Maryland, Baltimore
2008-06 – 2010-10 · Bipolar Disorder
What this study did
NCT00179062 · Vanderbilt University
2000-02 – 2007-06 · Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
What this study did
NCT00227123 · University of Texas Southwestern Medical Center
2002-10 – 2006-11 · Bipolar Disorder, Cocaine Dependence, Methamphetamine Dependence
What this study did
NCT00012558 · National Institute of Mental Health (NIMH)
1998-09 – 2005-09 · Bipolar Disorder
What this study did
Schizophrenia
NCT07523256 · Rinvil Renaldi
2025-11-01 – 2026-01-31 · Schizophrenia, Psychotic Disorders
What this study did
NCT07541157 · Hasanuddin University
2025-09-01 – 2026-01-31 · Schizophrenia Patients
What this study did
NCT00825045 · Centre for Addiction and Mental Health
2008-12 – 2020-12 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT02926976 · Shanghai Mental Health Center
2016-11 – 2019-09 · Schizophrenia
What this study did
NCT04076371 · Beijing HuiLongGuan Hospital
2012-01 – 2018-12 · Schizophrenia
What this study did
NCT02661347 · Northwell Health
2016-02 – 2016-12-01 · Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
What this study did
NCT00716755 · Centre for Addiction and Mental Health
2009-10 – 2015-08 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder, Psychotic Disorder
What this study did
NCT02573701 · Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
2011-10 – 2015-07 · Schizophrenia
What this study did
NCT01057849 · Peking University
2008-09 – 2011-03 · Schizophrenia
What this study did
NCT00206960 · Birte Glenthoj
1998-01 – 2010-09 · Schizophrenia
What this study did
NCT00515723 · Washington University School of Medicine
2001-09 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
What this study did
NCT00225498 · Northwell Health
2002-06 – 2008-10 · Schizophrenia
What this study did
NCT01234454 · University of North Carolina, Chapel Hill
2002-01 – 2007-12 · Schizophrenia
What this study did
NCT00169988 · Northwell Health
2004-03 – 2007-04 · Prodromal Schizophrenia, Psychotic Disorders
What this study did
NCT00006195 · National Center for Research Resources (NCRR)
— · Schizophrenia
What this study did
NCT00205738 · Washington University School of Medicine
2000-07 – 2006-10 · Schizophrenia, Type 2 Diabetes Mellitus
What this study did
NCT00222495 · University of Minnesota
2002-08 – 2006-08 · Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
What this study did
NCT00174200 · Pfizer
2004-12 – 2006-05 · Schizophrenia, Psychotic Disorders
What this study did
Other / comorbidity
NCT07060872 · Shahid Sadoughi University of Medical Sciences and Health Services
2025-07-07 – 2025-10-01 · Age 3 to 7 Years, Mild Autism Spectrum, no Other Illness or Disorder
What this study did
NCT05868720 · All India Institute of Medical Sciences, Bhubaneswar
2023-07-01 – 2025-03-02 · The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level
What this study did
NCT06200584 · Dr Rabia Arshad
2021-01-01 – 2021-06-10 · Antipsychotics and Neuroleptics Toxicity
What this study did
NCT04639960 · University of Geneva, Switzerland
2017-09-29 – 2021-05-01 · 22q11.2 Deletion Syndrome
What this study did
NCT01931059 · Northwell Health
2013-07 – 2016-07 · Imaging of the Brain and Antipsychotics, Neuronal Network Changes
What this study did
NCT02137616 · Central South University
2012-06 – 2014-12 · Psychotic Disorders
What this study did
NCT01896349 · Hospital de Clinicas de Porto Alegre
2013-04 – 2014-11 · Treatment Resistant Depression
What this study did
NCT01510015 · Tel-Aviv Sourasky Medical Center
2012-01 – 2013-11 · Cannabis Dependence, Psychostimulant Dependence
What this study did
NCT00389493 · New York State Psychiatric Institute
2006-10 – 2012-12 · Obsessive-Compulsive Disorder
What this study did
NCT00825552 · Federal University of Rio Grande do Sul
2009-01 – 2010-11 · Severe Mood Dysregulation
What this study did
NCT00723580 · Child Psychopharmacology Institute
2008-05 – 2010-08 · Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
What this study did
NCT00633802 · Tel-Aviv Sourasky Medical Center
2004-04 – 2009-04 · Borderlone Personality Disorder
What this study did
NCT00080145 · Yale University
2004-02 – 2007-09 · Child Development Disorders, Pervasive
What this study did
NCT00018291 · US Department of Veterans Affairs
2001-01 – 2005-01 · Alzheimer's Disease, Dementia
What this study did
NCT01222923 · Ranbaxy Laboratories Limited
2004-10 – 2005-01 · Healthy
What this study did
NCT01222975 · Ranbaxy Laboratories Limited
2004-10 – 2004-12 · Healthy
What this study did
NCT00015548 · National Institute of Mental Health (NIMH)
2001-03 – 2004-10 · Alzheimer's Disease
What this study did
NCT00203775 · University of Connecticut
2002-07 – 2004-04 · Psychosis, Aggression
What this study did
NCT00457106 · Beth Israel Medical Center
2002-06 – 2003-06 · Major Depression With Panic Attacks, Panic Disorder
What this study did
NCT00374764 · Washington University School of Medicine
2000-07 – 2002-06 · Autistic Disorder
What this study did
NCT00158028 · Icahn School of Medicine at Mount Sinai
1995-11 – 2001-12 · Schizotypal Personality Disorder
What this study did
Used as active comparator (87)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (17)
Bipolar Disorder
NCT00857818 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-04 – 2010-03 · Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
What this study did
Schizophrenia
NCT02469155 · Intra-Cellular Therapies, Inc.
2015-06 – 2016-08 · Schizophrenia
What this study did
NCT02002832 · Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
2013-12 – 2015-11 · Schizophrenia
What this study did
NCT02453893 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2013-11 – 2015-06 · Schizophrenia
What this study did
NCT01516424 · Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
2012-02 – 2013-02 · Schizophrenia
What this study did
NCT01295372 · H. Lundbeck A/S
2011-04 – 2012-10 · Schizophrenia
What this study did
NCT00641745 · Sumitomo Pharma America, Inc.
2008-03 – 2010-07 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00711269 · Sumitomo Pharma Co., Ltd.
2008-06-27 – 2010-04-27 · Schizophrenia
What this study did
NCT00640562 · AstraZeneca
2008-02 – 2010-02 · Schizophrenia, Depression
What this study did
NCT00604279 · Xian-Janssen Pharmaceutical Ltd.
2008-01 – 2009-01 · Schizophrenia
What this study did
NCT00366704 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-11 – 2008-03 · Schizophrenia
What this study did
NCT00856583 · H. Lundbeck A/S
2002-07 – 2008-02 · Schizophrenia
What this study did
NCT00645372 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-07 – 2005-05 · Schizophrenia
What this study did
NCT00645515 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-06 – 2003-12 · Schizophrenia
What this study did
Other / comorbidity
NCT00600756 · AstraZeneca
2008-01 – 2009-10 · Schizophrenic Disorders
What this study did
NCT00660595 · AstraZeneca
2008-09 – 2008-12 · Schizophrenic Disorders
What this study did
Phase 2/3 (5)
Schizophrenia
NCT01626872 · Tanabe Pharma Corporation
2012-09 – 2016-10 · Schizophrenia
What this study did
NCT01625000 · Tanabe Pharma Corporation
2012-05 – 2015-10 · Schizophrenia
What this study did
NCT01625897 · Tanabe Pharma Corporation
2012-05 – 2015-03 · Schizophrenia
What this study did
NCT01363349 · BioLineRx, Ltd.
2011-05 – 2013-04 · Schizophrenia, Cognitive Effect on Schizophrenic Patients
What this study did
NCT01129674 · Denovo Biopharma LLC
2010-06 – 2012-10 · Schizophrenia
What this study did
Phase 2 (18)
Schizophrenia
NCT04624243 · Merck Sharp & Dohme LLC
2020-12-15 – 2024-06-21 · Schizophrenia
What this study did
NCT04512066 · Hoffmann-La Roche
2020-09-08 – 2022-06-21 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT03055338 · Merck Sharp & Dohme LLC
2017-03-08 – 2018-01-09 · Schizophrenia, Acute Episode
What this study did
NCT01623713 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2012-06 – 2013-11 · Schizophrenia, Iloperidone, Efficacy
What this study did
NCT01499563 · Intra-Cellular Therapies, Inc.
2011-12 – 2013-11 · Schizophrenia
What this study did
NCT01086748 · Denovo Biopharma LLC
2010-03 – 2012-05 · Schizophrenia
What this study did
NCT00845026 · Denovo Biopharma LLC
2009-03 – 2010-12 · Schizophrenia
What this study did
NCT00722176 · BioLineRx, Ltd.
2008-06 – 2009-12 · Schizophrenia
What this study did
NCT00567710 · BioLineRx, Ltd.
2008-07 – 2009-09 · Schizophrenia
What this study did
NCT00694707 · Forest Laboratories
2008-06-30 – 2009-08-31 · Schizophrenia
What this study did
NCT00768612 · Wyeth is now a wholly owned subsidiary of Pfizer
2008-11 – 2009-07 · Schizophrenia
What this study did
NCT00563706 · Pfizer
2007-12 – 2008-06 · Schizophrenia
What this study did
NCT00103727 · GlaxoSmithKline
2004-12 – 2005-10 · Schizophrenia
What this study did
Other / comorbidity
NCT05401019 · Clinical Academic Center (2CA-Braga)
2022-06 – 2026-12 · Obsessive-Compulsive Disorder
What this study did
NCT05710237 · Centre for Addiction and Mental Health
2023-07-01 – 2026-04-14 · Treatment-resistant Depression
What this study did
NCT04105231 · Lone Baandrup
2021-06-01 – 2026-03-31 · Dual Diagnosis
What this study did
NCT04529226 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2020-11-26 – 2025-12-30 · Psychosis, Intellectual Disability
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06368726 · Spanish Foundation for Neurometrics Development
2024-04-01 – 2026-09-02 · Attention, Visual Perceptual Weakness, Social Behavior, Fluency Disorder, EEG With Periodic Abnormalities
What this study did
Phase 1 (8)
Schizophrenia
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
NCT02411526 · Zogenix, Inc.
2015-02 – 2015-09 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT02186769 · Luye Pharma Group Ltd.
2014-07 – 2015-04 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT02091388 · Luye Pharma Group Ltd.
2014-09 – 2015-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01376076 · Forest Laboratories
2011-06 – 2012-02 · Schizophrenia
What this study did
Other / comorbidity
NCT01722201 · IPCA Laboratories Ltd.
2012-06 – 2012-09 · Fasting
What this study did
NCT01618760 · IPCA Laboratories Ltd.
2012-05 – 2012-06 · Fed
What this study did
Phase 4 (33)
Bipolar Disorder
NCT04580134 · University of Texas Southwestern Medical Center
2022-03-01 – 2027-04-30 · Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
What this study did
NCT02562287 · Hospital de Clinicas de Porto Alegre
2015-10 – 2020-12 · Bipolar Disorder
What this study did
Schizophrenia
NCT06236451 · All India Institute of Medical Sciences, Bhubaneswar
2024-04-05 – 2025-11-12 · Schizophrenia
What this study did
NCT01451736 · University of California, Los Angeles
2011-10 – 2021-12-31 · Schizophrenia (Recent-onset)
What this study did
NCT03075657 · All India Institute of Medical Sciences, Bhubaneswar
2017-05-01 – 2018-08-31 · Schizophrenia
What this study did
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT01639872 · Dartmouth-Hitchcock Medical Center
2013-05-01 – 2017-03-29 · Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
What this study did
NCT01913327 · University of California, San Francisco
2013-04 – 2017-01 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT01157351 · Janssen Scientific Affairs, LLC
2010-05 – 2013-12 · Schizophrenia
What this study did
NCT00330551 · University of California, Los Angeles
2006-03 – 2012-11 · Schizophrenia
What this study did
NCT01193166 · Ortho-McNeil Janssen Scientific Affairs, LLC
2010-08 – 2012-09 · Schizophrenia
What this study did
NCT00480844 · Sheba Medical Center
2008-10 – 2011-10 · Schizophrenia
What this study did
NCT00827840 · Chonnam National University Hospital
2008-11 – 2011-02 · Schizophrenia
What this study did
NCT00330863 · Northwell Health
2006-05 – 2011-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00352339 · Inje University
2006-08 – 2010-12 · Schizophrenia
What this study did
NCT00992407 · Janssen Korea, Ltd., Korea
2007-12 – 2010-12 · Schizophrenia
What this study did
NCT00130923 · Dartmouth-Hitchcock Medical Center
2005-09 – 2010-07 · Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
What this study did
NCT00817648 · Shanghai Mental Health Center
2008-12 – 2010-05 · Schizophrenia
What this study did
NCT00946985 · Ortho-McNeil Janssen Scientific Affairs, LLC
2009-06 – 2010-03 · Schizophrenia
What this study did
NCT00423878 · National Institute of Mental Health (NIMH)
2007-01 – 2010-03 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00418873 · Astellas Pharma Inc
2007-03 – 2009-12 · Schizophrenia
What this study did
NCT00508157 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2007-11-01 – 2009-03-01 · Metabolic Syndrome, Schizophrenia
What this study did
NCT00206102 · AstraZeneca
2003-09 – 2008-10 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00190749 · Eli Lilly and Company
2003-10 – 2008-06 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00654576 · Central South University
2005-02 – 2007-12 · Schizophrenia
What this study did
NCT00337662 · Eli Lilly and Company
2006-05 – 2007-12 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
Other / comorbidity
NCT05890768 · University of New Mexico
2023-05-11 – 2024-02-28 · Psychosis
What this study did
NCT01813643 · Wei Hao
2012-07 – 2014-08 · Methamphetamine Dependence
What this study did
NCT01822730 · Wei Hao
2013-02 – 2014-05 · Methamphetamine Dependence
What this study did
NCT00806234 · Johns Hopkins University
2009-01 – 2014-03 · Psychotic Disorders
What this study did
NCT00621998 · Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
2000-07 – 2004-06 · Neuroleptic-Induced Tardive Dyskinesia
What this study did
Early phase / not applicable (5)
Schizophrenia
NCT02192723 · Beijing HuiLongGuan Hospital
2012-06 – 2014-06 · Schizophrenia
What this study did
NCT00629252 · University of Zurich
2008-02 – 2012-08 · Schizophrenia
What this study did
NCT00573287 · Dartmouth-Hitchcock Medical Center
2006-06 – 2011-12 · Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
What this study did
NCT00534183 · Central Institute of Psychiatry, Ranchi, India
2006-06 – 2006-12 · Metabolic Syndrome, Diabetes, Obesity
What this study did
Other / comorbidity
NCT06581302 · Shanghai Jiao Tong University School of Medicine
2024-09-01 – 2025-12-30 · Psychotic Disorders
What this study did
Appears in other studies (45)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (13)
Bipolar Disorder
NCT00391222 · Janssen Pharmaceutica N.V., Belgium
2006-11 – 2009-04 · Bipolar Disorder
What this study did
Schizophrenia
NCT00435370 · Baylor College of Medicine
2006-11 – 2011-08 · Smoking Cessation, Schizophrenia
What this study did
NCT00132314 · US Department of Veterans Affairs
2006-09 – 2009-09 · Schizoaffective Disorder, Schizophrenia
What this study did
NCT00216476 · Janssen-Cilag International NV
2004-10 – 2007-11 · Schizophrenia, Psychotic Disorders
What this study did
NCT01888107 · Janssen-Cilag S.p.A.
2005-01 – 2007-04 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00843687 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-09 – 2007-03 · Schizophrenia
What this study did
NCT00216580 · Janssen Pharmaceutica N.V., Belgium
2004-02 – 2006-12 · Schizophrenia
What this study did
NCT00828958 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-02 – 2006-09 · Schizophrenia
What this study did
NCT00237913 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-07 – 2005-08 · Schizophrenia
What this study did
NCT00297388 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
est. completion 2004-09 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00159770 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2001-11 – 2004-09 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
What this study did
NCT00249223 · Janssen Pharmaceutica N.V., Belgium
2000-01 – 2000-12 · Schizophrenia, Psychotic Disorders
What this study did
Phase 2 (7)
Schizophrenia
NCT07575516 · Hasanuddin University
2025-10-01 – 2026-01-31 · Schizophrenia Patients, Neuroinflammation
What this study did
NCT07477301 · Hasanuddin University
2024-12-01 – 2025-02-28 · Schizophrenia, Cognitive Dysfunction, Inflamation
What this study did
NCT03557931 · Astellas Pharma Global Development, Inc.
2018-07-13 – 2019-10-21 · Schizophrenia
What this study did
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
Other / comorbidity
NCT06768944 · University of Calgary
2026-05-15 – 2028-01 · Investigating the Importance of the Subjective Psychedelic Experience
What this study did
NCT06512220 · Centre for Addiction and Mental Health
2025-04-21 – 2027-09 · Treatment Resistant Depression
What this study did
NCT00284206 · Seattle Institute for Biomedical and Clinical Research
2006-01 – 2007-08 · Methamphetamine Dependence
What this study did
Phase 1/2 (1)
Schizophrenia
NCT00653406 · Janssen Pharmaceutical K.K.
2002-11 – 2003-10 · Schizophrenia
What this study did
Phase 1 (3)
Schizophrenia
NCT00821600 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-12 – 2009-06 · Psychotic Disorders, Schizophrenia
What this study did
Other / comorbidity
NCT07490353 · Medical University of Vienna
2025-11-01 – 2028-05-31 · Depression - Major Depressive Disorder, Anhedonia
What this study did
NCT07503002 · Johns Hopkins University
2026-12-01 – 2027-12-01 · Major Depression Moderate, Major Depression Severe, Major Depression
What this study did
Phase 4 (14)
Bipolar Disorder
NCT07047651 · Dr. Stavroula Rakitzi
2025-06-04 – 2027-12-20 · Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
What this study did
Schizophrenia
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did
NCT00539071 · Northwestern University
2008-03 – 2012-05 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00246259 · Janssen-Ortho Inc., Canada
2004-10 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
What this study did
NCT00269919 · Janssen Korea, Ltd., Korea
2005-08 – 2008-08 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01726335 · Janssen-Cilag Ltd.
2006-01 – 2008-03 · Schizophrenia
What this study did
NCT00369239 · Janssen Pharmaceutica N.V., Belgium
2006-03 – 2007-11 · Schizophrenia, Psychotic Disorders, Schizoaffective Disorder
What this study did
NCT00304616 · Korea Otsuka Pharmaceutical Co., Ltd.
2004-10 – 2007-10 · Schizophrenia
What this study did
NCT00325689 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-07 – 2007-10 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00893256 · National Institute of Mental Health and Neuro Sciences, India
2004-12 – 2007-09 · Schizophrenia, Negative Symptoms
What this study did
NCT00203788 · University of California, Los Angeles
1999-05 – 2006-12 · Schizophrenia
What this study did
NCT00215579 · Duke University
2004-04 – 2006-04 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT00768820 · The Chaim Sheba Medical Center
2001-05 – 2027-08 · Velocardiofacial Syndrome, Williams Syndrome, Fragile X Syndrome
What this study did
Early phase / not applicable (7)
Schizophrenia
NCT07524868 · Hasanuddin University
2025-11-01 – 2026-01-31 · Schizophrenia Patients, Auditory Hallucination
What this study did
NCT07609953 · Hasanuddin University
2025-11-01 – 2026-01-31 · Schizophrenia
What this study did
NCT07671040 · Hasanuddin University
2025-03-01 – 2025-06-30 · Schizophrenia, Cognitive and Executive Dysfunction, Neuroinflammation
What this study did
NCT07116850 · The First Hospital of Hebei Medical University
2024-01-01 – 2024-12-31 · Schizophrenia Disorder
What this study did
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did
NCT00493233 · Centre for Addiction and Mental Health
2006-11 – 2008-12 · Schizophrenia
What this study did
NCT00563017 · Hospital Authority, Hong Kong
2004-10 – 2005-11 · Schizophrenia, Catatonic, Schizophrenia, Disorganized, Schizophrenia, Paranoid, Schizophrenia, Psychotic Disorders
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Schizophrenia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Risperidone (Risperdal): this drugApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)Reliable signal
NCT03172871: LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin
NCT00706654: Impending relapse by week 26: aripiprazole once-monthly 400 mg 7.12% vs oral aripiprazole 10-30 mg 7.76% (non-inferior); low-dose depot reference arm 21.80%
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT00712686: Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05).
Aripiprazole Lauroxil (Aristada Initio)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole Lauroxil (Aristada)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorReliable signal
NCT01469039: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39)
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00212771: Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint
NCT00212784: Change in total PANSS score (52-week active-controlled trial): asenapine -21.0 vs olanzapine -27.5, difference P<0.0001. missed
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT03198078: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014
NCT01396421: Change in PANSS total score at Week 6 vs placebo: brexpiprazole 2 mg treatment difference -8.72; 4 mg treatment difference -7.64 (both statistically significant).
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Reliable signal
NCT01104766: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4)
NCT01104779: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline to Week 6): Cariprazine (3-6 mg/Day) -22.8 Units on a Scale (Standard Error 1.6) | Cariprazine (6-9 mg/Day) -25.9 Units on a Scale (Standard Error 1.7) vs Placebo -16 Units on a Scale (Standard Error 1.6)
ClozapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT03510325: Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed.
Haloperidol
ApprovedUS marketing discontinued
Small moleculeDopamine D2 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00254202: Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2).
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorPartial signal
NCT04959032: Study 304 (NCT04959032), time to relapse during double-blind phase: HR 0.37 (95% CI 0.22-0.65), 63% relapse-risk reduction vs placebo (p=0.0002); relapse rate 16.4% (18 relapses) lumateperone vs 38.6% (44 relapses) placebo
NCT02469155: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks): Lumateperone 14 mg (ITI-007 20 mg Tosylate) -15 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.6 units on a scale (Standard Error 1.23) vs Placebo -15.1 units on a scale (Standard Error 1.21) | Risperidone -20.5 units on a scale (Standard Error 1.33) missed
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03465787: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority.
NCT00549718: Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks): Lurasidone 40mg -19.2 scores on a scale (95% CI -22.6 to -15.7) | Lurasidone 80mg -23.4 scores on a scale (95% CI -26.9 to -19.9) | Lurasidone 120mg -20.5 scores on a scale (95% CI -24 to -17.1) vs Placebo -17 scores on a scale (95% CI -20.5 to -13.6)
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Weltruza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Reliable signal
NCT05693935: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8): Double-blind: TV-44749 318 mg -21.91 units on a scale (95% CI -25.13 to -18.7) | Double-blind: TV-44749 425 mg -23.44 units on a scale (95% CI -26.52 to -20.36) | Double-blind: TV-44749 531 mg -21.93 units on a scale (95% CI -25.01 to -18.85) vs Double-blind: Placebo -12.17 units on a scale (95% CI -15.34 to -8.99)
Olanzapine (Zyprexa Relprevv)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00088478: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each).
NCT00320489: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) (Baseline up to 104 weeks): Olanzapine Pamoate Depot 644.5 Days (IQR 162 to 740) vs Oral Olanzapine 677.5 Days (IQR 169.5 to 740) missed
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT03510325: Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 missed
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signal
NCT03187769: Percent change from baseline in body weight at Week 12: 4.91% ALKS 3831 vs 6.77% olanzapine; least-squares mean difference −1.87 percentage points (95% CI −3.33 to −0.41; p=0.012).
NCT02634346: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks): ALKS 3831 -23.9 units on a scale (Standard Error 1.28) vs Olanzapine -22.8 units on a scale (Standard Error 1.29) vs Placebo -17.5 units on a scale (Standard Error 1.32)
Paliperidone (Invega)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet graded
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 phase 3 result · pivotal pending
Paliperidone Palmitate (Erzofri)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (Invega Sustenna)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT02431702: Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). missed
NCT00101634: PANSS total improved vs placebo in all three fixed-dose groups (p=0.02 for 25 and 50 mg equiv., p<0.001 for 100 mg equiv.).
Paliperidone Palmitate (Invega Trinza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178
NCT02713282: Symptomatic remission (Andreasen PANSS criteria) at LOCF/Month 12 endpoint: 172/303 patients, 56.8% (95% CI 51.0-62.4)
Perseris
ApprovedUS marketing discontinued
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT02109562: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT00640601: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8)
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00305422: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00253136: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly.
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03503318: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181
Xanomeline / Trospium Chloride (Cobenfy)ApprovedSmall moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)Reliable signal
NCT04738123: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5): KarXT -20.6 Score on a scale (Standard Error 1.584) vs Placebo -12.2 Score on a scale (Standard Error 1.552)
NCT04659161: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5): KarXT -21.2 score on a scale (Standard Deviation 1.652) vs Placebo -11.6 score on a scale (Standard Deviation 1.6)
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00403546: Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). missed
NCT00159770: Ziprasidone non-inferior to the olanzapine/risperidone/quetiapine group on total PANSS (margin 7 units; P<0.0001).
Cariprazine (Chengdu Kanghong)Phase 3Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (QLM1016)Phase 3Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signal
NCT04268303: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours): 120 Micrograms — Baseline: 17.5 score on a scale (Standard Deviation 2.46); 2 Hours: -8.4 score on a scale (Standard Deviation 4.83) | 180 Micrograms — Baseline: 17.6 score on a scale (Standard Deviation 2.69); 2 Hours: -10.4 score on a scale (Standard Deviation 4.34) vs Placebo — Baseline: 17.6 score on a scale (Standard Deviation 2.26); 2 Hours: -4.7 score on a scale (Standard Deviation 4.69)
NCT05658510: Primary endpoint (SERENITY III Part 1, change from baseline in PEC total score at 2 hours), drug vs placebo: p=0.077, not statistically significant.
DireclidinePhase 3Small moleculeMuscarinic M4 receptorPartial signal
NCT05545111: PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline
HS-10380Phase 3Small moleculeDopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target)Partial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)Phase 3Small moleculeDopamine D2/D3 receptor + 5-HT7 receptorReliable signal
NCT06179108: Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): LB-102, 50 mg QD -14.28 score on a scale ± 1.097 vs LB-102, 75 mg QD -13.95 score on a scale ± 1.108 vs LB-102, 100 mg -16.08 score on a scale ± 1.906 vs Placebo Comparator -9.27 score on a scale ± 1.078; p=0.0009 (LB-102, 50 mg QD vs Placebo Comparator), p=0.0022 (LB-102, 75 mg QD vs Placebo Comparator), p=.0017 (LB-102, 100 mg vs Placebo Comparator)
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00628589: Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92)
Olanzapine / Samidorphan (Qilu)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist), Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
RoluperidonePhase 3Small moleculeSigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist)Partial signal
NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed
UlotarontPhase 3Small moleculeTAAR1 (trace amine-associated receptor 1)Partial signal
NCT04092686: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): SEP-363856 75mg -16.4 score on a scale (Standard Error 1.49) | SEP-363856 100mg -18.1 score on a scale (Standard Error 1.5) vs Placebo -14.3 score on a scale (Standard Error 1.47) missed
NCT04072354: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): Adults: SEP-363856 50mg -16.9 score on a scale (Standard Error 1.57) | Adults: SEP-363856 75mg -19.6 score on a scale (Standard Error 1.56) vs Adults: Placebo -19.3 score on a scale (Standard Error 1.55) missed
ANAVEX3-71Phase 2Small moleculeSigma-1 receptor / muscarinic receptor (dual)Partial signal
NCT06245213: ANAVEX3-71-SZ-001 (NCT06245213) achieved its primary endpoint: ANAVEX3-71 was safe and well-tolerated, with no serious TEAEs and no severe TEAEs in either Part A or Part B.
Balipodect (TAK-063)Phase 2Small moleculePhosphodiesterase 10A (PDE10A)Partial signal
NCT02477020: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 (Baseline and Week 6): TAK-063 -19.54 score on a scale (Standard Error 2.412) vs Placebo -14.08 score on a scale (Standard Error 2.474) missed
Betovumeline / Fesoterodine (ML-007C-MA)Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)Partial signal
NCT07038876: PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed.
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CPL500036Phase 2Small moleculePDE10AReliable signal
NCT05278156: Change from baseline in PANSS positive subscale at Day 28 (Week 4): 20 mg dose improved 3.7 points (p<0.001, Cohen's d=0.73); 40 mg dose improved 6.3 points (p<0.001, Cohen's d=1.38)
EmraclidinePhase 2Small moleculeMuscarinic M4 receptorPartial signal
NCT05227703: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) missed
GXV813Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
LY03020Phase 2Small molecule5-HT2C/TAAR1 receptorWeak signalNo reviewed efficacy summary in this indication
NBI-1117570Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2Small moleculeDendritic spine densitynot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VV119Phase 2Small moleculeDopamine and serotonin receptors (multi-target antipsychotic)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine Long-Acting Injection (Mapi Pharma)Phase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
JX11502MAPhase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)Weak signal
NCT05233657: JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%).
AticaprantPhase 1Small moleculeKappa-opioid receptor (inhibitor), Kappa opioid receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole Long-Acting Injection (Kelun)Phase 1Small moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
HS-10509Phase 1Small molecule—Partial signalNo reviewed efficacy summary in this indication
LY03017Phase 1Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptorWeak signalNo reviewed efficacy summary in this indication
NTX-253Phase 1Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Risperidone (QUAR)Phase 1Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (CSPC)
—(overall)
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)Weak signal
NCT03892889: Percentage of Participants With Inpatient Psychiatric Hospitalization (Retrospective Period [Month -6 to Baseline (Day 1)] up to Prospective Period (Day 1 to Month 3)): Abilify MyCite® 0%
AVP-786DiscontinuedCombinationsigma-1/NMDAnot yet gradedNo reviewed efficacy summary in this indication
Clozapine (Fazaclo)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication
NeloniclineDiscontinuedSmall moleculenicotinic acetylcholine receptor alpha7 (alpha7 nAChR)Partial signal
NCT01655680: MCCB neurocognitive composite, change from baseline to week 12 (primary analysis, ABT-126 50 mg vs placebo): +2.66 (±0.54) vs +2.46 (±0.56), P>0.05; 432 randomized. The UPSA-2ER key secondary also showed no significant difference. missed
Risperidone (Risvan)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03160521: PANSS Total Score Mean Change From Baseline to Endpoint (Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)): Risperidone ISM 75 mg -24.6 units on a scale (Standard Error 1.51) | Risperidone ISM 100 mg -24.7 units on a scale (Standard Error 1.54) vs Placebo -11 units on a scale (Standard Error 1.56)
Rosiglitazone (Avandia)DiscontinuedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Risperidone (Risperdal) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 4SchizophreniaRecruiting
Est. primary completion 2027-09-30 · NCT04478838 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 4Bipolar DisorderNot yet recruiting
Est. primary completion 2028-06 · NCT07665073 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 4Psychosis; AcuteRecruiting
Est. primary completion 2029-12-01 · NCT07483294 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 4SchizophreniaRecruiting
Est. primary completion 2030-07-30 · NCT06969755 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Phase 2SchizophreniaNot yet recruiting
Est. primary completion 2032-02-01 · NCT07152184 · CT.gov ↗
What to watch

See the full readout calendar ↗